胃肠粘膜保护相关双抗文献.pdfVIP

ORIGINALARTICLE

CYP2C19GeneticPolymorphism,Rabeprazoleand

EsomeprazoleHavenoEffectontheAntiplatelet

ActionofClopidogrel

MustaphaM.El-Halabi,MD,*NathalieZgheib,MD,†NabilM.Mansour,MD,*AhmadMalli,MD,*

OlaA.Ghaith,MD,*RamiMahfouz,MD,‡SamirAlam,MD,§an.Sharara,MD*

Onmultivariatelogisticregression,neitherCYP2C19LOFalleles

:TheaimofthisstudyistoinvestigatetheeffectofnorprotonpumpinhibitorcotherapywereassociatedwithHPR.

CYP2C19polymorphismandcotherapywithrabeprazoleorTheuseofprotonpumpinhibitorswasindicatedin30.6%of

esomeprazoleontheantiplateleteffectofclopidogrel.Patientsrecipients.Asaconclusion,CYP2C19*2LOFalleleandtheuse

receivingclopidogrel75mg6rabeprazoleoresomeprazoleofesomeprazoleorrabeprazolehavenoeffectontheactionof

underwentgenotypingforCYP2C19*2andCYP2C19*3,andclopidogrel.

vasodilator-stimulatedphosphoproteintestingtomeasureplatelet

reactivityindex(PRI).Twohundredthirty-nineconsecutiveKeyWords:protonpumpinhibitors,plateletreactivityindex,high

patientswereenrolledasfollows:92clopidogrel(Cgroup),94on-treatmentplateletreactivity,CYP450,metabolism,pharmacody-

clopidogrel+rabeprazole(CR),and53clopidogrel+esomepra-namic,druginteraction

zole(CE).Forty-fivepatientshadlossoffunction(LOF)poly-(JCardiovascPharmacolÔ2013;62:41–49)

morphism(43heterozygous;2homozygous